You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

RSV STOPS NOW!

The FIRST Respiratory syncytial virus (RSV)  Vaccine with an adjuvant NOW AVAILABLE in the Philippines, with demonstrated efficacy for patients aged 60 years and older1-6

Quick links

Resources 

Therapy Areas

Prescribing Information

 

Expert Videos

Shingrix Must Watch

Trelegy Must Watch

Augmentin Sci-flix

Get More From GSKPro

Order Vaccines

Contact Us 

 

Nucala battle tested campaign imagery

Make a difference for your symptomatic COPD patients at risk of exacerbations7

 Therapy Areas

Respiratory

Respiratory

Access information about GSK Respiratory products as well as continuing medical education (CME) resources on the management of asthma and COPD relevant to your daily clinical practice.

Learn more

vaccines

Vaccines

Discover the wide array of vaccines in the GSK portfolio, stay up-to-date on the latest information about information and access resources beyond the antigen.

Learn more

Zejula Logo

Other Therapy Areas

Access product information and resources relevant to your daily clinical practice for the following:

Allergy | Anti-Infectives | Dermatology | Central Nervous System | Urology

Learn more

IF YOU CAN PREVENT SHINGLES SUFFERING, WHY WOULDN'T YOU8?

Vaccinate now for protection that last8*

 More Information

idenityfy Patients

Identify Patients With COPD

How can you identify patients with Chronic Obstructive Pulmonary Disease who say they feel okay but could be struggling with their daily activities?

COPD PATIENTS

Prescribing information

asian women

Dominant Driver of Shingles

You may have heard about how serious the pain of shingles can be. Learn more about the signs, symptoms, complications & prevention options

CAUSES

Prescribing information

Zejula Logo

Fight against Anti-microbial resistance (AMR)

Major international guidelines recommend a combination of amoxicillin and clavulanic acid to treat a wide variety of bacterial infections. 

GUIDELINES

Prescribing information

References:

  1. Arexvy Certificate of Product Registration;
  2. Arexvy Local Prescribing Information GDS02 IP101 24 May 2023
  3. Falsey AR, Walsh EE, House S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults— a global study during the 2017-2019 epidemic seasons (hospitalized acute respiratory tract infection [HART I] study). Open Forum Infect Dis. doi:10.1093/ofid/ofab491
  4. Wilson E et al. Safety and efficacy of mRNA-1345, an mRNA-based vaccine against respiratory syncytial virus, in adults 60 years and older (oral presentation). Presented at RSSVW'23, 22-24 February 2023, Lisbon, Portugal. https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2023/09/RSV-09-13-23.pdf
  5. Papi A et al. N Engl J Med 2023;388(7):595–608
  6. Respiratory syncytial virus vaccine, Global Full Prescribing Information; www.pfizer.com; retrieved on February 2024
  7. Trelegy Prescribing Information version number : GDS06/IPI06.1 Revision date: 08 June 2021
  8. Shingrix Prescribing Information GDS07/IPI02 / Date of issue: 14 June 2022

Trade marks are owned by or licensed to GSK group of companies.

Kindly forward all adverse events and product complaint to GSK Philippines via these contact details: Adverse event: ph.safety@gsk.com; Product complaint: PHLOC_complaints@gsk.com or 0917 889 7050

PM-PH-NA-WCNT-190003 | April 2024